In May, 2017, the service-based gig economy is coming to a lab near you - a paradigm shift that will get its start in Boston's thriving biopharmaceutical ecosystem. As the pool of academic tenure-track positions shrinks, federal research dollars tighten, and pharmaceutical companies and investment firms seek to be more nimble in developing products, a solution is being offered through a platform called LabMate.
Harvard Stem Cell Institute (HSCI) invites applications for seed grant funding for its 2017 cycle. The purpose of this program is to provide funding for innovative projects in the field of stem cell and regenerative biology. As was the case last year, HSCI strongly encourages proposals with a translational focus, or which are otherwise poised to accelerate the development of new stem cell-based therapies or cures. However, proposals at all stages of development are welcome. HSCI intends to award up to ten grants in response to this request for proposals, contingent upon the number and… Read more about Request for Proposals: HSCI Seed Grant Program 2017
The Harvard Stem Cell Institute (HSCI) is pleased to announce the success of the 2015–16 General Fund Matching Challenge. Throughout fiscal year 2016, HSCI saw an outpouring of unrestricted funding, resulting in $2.6 million in new gifts and pledges. This support came from over 110 donors making commitments at a variety of levels, with many new donors… Read more about HSCI Matching Challenge Update
Cambridge, MA, June 16,2016 - The Harvard Stem Cell Institute, three of Harvard’s clinical affiliates, and a biopharmaceutical company have formed a unique collaboration to establish the Boston Autologous Islet Replacement Program (BAIRT) to accelerate a cure for diabetes.